May 6, 2020 News by Marta Figueiredo, PhD COVID-19 Infection Not Severe in PPMS Patient on Ocrevus, Case Report Finds COVID-19 infection in a multiple sclerosis (MS) patient being treated withĀ Ocrevus (ocrelizumab) ā an immunosuppressive therapy ā was not associated with any serious complications, a case study reports. This finding supports current suggestions that immunosuppressive therapies, by dampening immune and inflammatory responses, may help to protect…
April 29, 2020 News by Marisa Wexler, MS Ocrevus’ Early Use May Lower Need for Walking Aid by 49% Over 6 Years StartingĀ treatment with OcrevusĀ early can lower almost by half the need for a walking aid inĀ peopleĀ with relapsing forms ofĀ multiple sclerosis (MS) over six years, new analyses of Phase 3 trial data that compared immediate initiation with a two-year delay show. A separate analysis also found…
April 21, 2020 News by Marisa Wexler, MS Shorter Ocrevus Infusion Time Up for Approval in US and Europe The U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted applications from Genentech to shorten the infusion time for Ocrevus, an approved treatment forĀ multiple sclerosis. If approved, the time to administer Ocrevus will be shortened to a two-hour session, instead…
April 3, 2020 News by Joana Carvalho, PhD Ocrevus Lowers Progression Risk in More Disabled MS Patients, Study Suggests For multiple sclerosis (MS) patients with considerable disability, Ocrevus (ocrelizumab) appears to lower the risk of continued progression in both relapsing and primary progressiveĀ forms of the disease, data from an exploratory and post-hoc analysis of three Phase 3 trials report. These findings were in the study, ā…
March 4, 2020 News by Ana Pena PhD #ACTRIMS2020 – 3 Ways to Treat MS by Altering Gut Microbiome Under Study Modulating the bacteria that reside in the gut by treatingĀ multiple sclerosis (MS) patients with probiotics, fecal transplants, or gut-related microRNAs may help to ease inflammation and disease severity,Ā researchers withĀ Brigham and Women’s Hospital suggest. Howard Weiner, MD, a group leader at the hospital, presented his team’s findings on…
February 14, 2020 News by Ana Pena PhD Ocrevus Use Rises Among New Starters with RRMS, Loses Ground to Other Therapies in PPMS First-line use of Genentech‘s Ocrevus (ocrelizumab) for patients with multiple sclerosis (MS) has remained stable through 2019 compared to 2018, according to the latest Spherix Global Insights‘ report. However, the latest edition of “RealWorld Dynamix: DMT New Starts in Multiple Sclerosis (US),” based…
January 16, 2020 News by Marisa Wexler, MS Scottish Medicines Consortium Approves Ocrevus for Treating PPMS Ocrevus (ocrelizumab) has been approved in Scotland as a treatment for early, inflammatory primary progressive multiple sclerosis (PPMS). The Scottish Medicines Consortium (SMC) has advised that OcrevusĀ can be prescribed by the National Health Service (NHS) forĀ people with PPMS who have had symptoms for less than 15…
November 22, 2019 News by Ana Pena PhD Ocrevus Top Choice of US Neurologists for Active SPMS, But Mayzent and Mavenclad Gaining Interest, Report Says Genentech‘sĀ OcrevusĀ (ocrelizumab) continues to be the most prescribed medication to reduce inflammatory disease in people with active secondary progressive multiple sclerosisĀ (SPMS) amongĀ U.S. neurologists, even though Novartis’Ā MayzentĀ (siponimod) and EMD Serono’sĀ MavencladĀ (cladribine) were approved in March to treat this same MS…
September 19, 2019 News by Ana Pena PhD #ECTRIMS2019 – Ocrevus Living Up to ‘Game-changing’ Moniker, Genentech’s Hideki Garren Says in Interview Two years after the approval of Ocrevus (ocrelizumab), the latest data continue to support the benefits of the so-called “game-changing” therapy in multiple sclerosis (MS), while new insights highlight its neuronal protective effects and safety. Multiple Sclerosis News Today had the opportunity to speak with Hideki Garren,…
September 17, 2019 News by Ana Pena PhD #ECTRIMS2019 – Early Ocrevus Use Slows Disability in PPMS, Including Risk of Wheelchair Reliance Early and continuous treatment with Ocrevus (ocrelizumab) leads to a greater and more durable slowing of disability progression ā seen for up to 6.5 years ā in people with primary progressive multiple sclerosis (PPMS), according to long-term data on its use in PPMS patients in a Phase 3…
September 16, 2019 News by Jose Marques Lopes, PhD #ECTRIMS2019 – Newer DMTs More Effective Than Older Injectables in Pediatric MS, Study Says Using newer disease-modifying therapies (DMTs) as an initial treatment for children and adolescents with multiple sclerosis (MS) or clinically isolated syndrome (CIS) is associated with fewer relapses and brain lesions compared to the use of older and injectable DMTs, according to a real-world study in the U.S.
September 12, 2019 News by Jose Marques Lopes, PhD #ECTRIMS2019 – No Retinal Thinning with Ocrevus in Relapsing MS Patients, Phase 3 Trials Show Treating relapsing multiple sclerosis (MS) patients with Ocrevus (ocrelizumab) is not associated with retinal thinning ā unlike treatment with Rebif (interferon beta-1a), according to two Phase 3 trials. The findings also showed a link between retinal thinning and brain volume loss. The study, ā…
September 12, 2019 News by Patricia Inacio, PhD #ECTRIMS2019 – 6 Years of Ocrevus Use Tied to Low Rates of Serious Infections Treatment for more than six years with OcrevusĀ (ocrelizumab) is linked to lower levels of blood antibodies among people withĀ primary progressive multiple sclerosis (PPMS) and relapsing MS, but rates of serious infections also remain low, an analysis of data from three Phase 3 trials show. Dropping below a certain…
August 23, 2019 News by Ana Pena PhD Rituximab Leads to ‘Dramatic’ Recovery in Boy with Aggressive RRMS, Case Study Reports Treatment with rituximabĀ ā sold as RituxanĀ in the U.S. by RocheĀ and Biogen, and asĀ MabThera byĀ Roche in Europe ā reversed disease course in a “dramatic fashion,” leading to complete remission in a 12-year-old boy with aggressiveĀ relapse-remitting multiple sclerosis (RRMS), a case report states. The report, “…
August 21, 2019 Columns by Stephanie Towler The Clinical Trial I Participated in Was a Positive Experience I knew nothing about multiple sclerosis (MS) before 2012, including the cause, the cure, or any other details. I had so many unanswered questions about how I would live with MS when I was diagnosed. I had never heard of treatment for MS and was unsure of the…
August 21, 2019 News by Joana Carvalho, PhD Immune System Molecule IL-17A Likely Inflammatory Agent in RRMS, Study Says Interleukin-17A (IL-17A), a molecule that mediates immune and inflammatory responses, likely promotes inflammation and tissue damage in relapsing-remitting multiple sclerosis (RRMS) and should be considered a potential target for treating the disease, a study reports. The findings of the study, “IL-17A is associated with the breakdown of the…
August 2, 2019 Columns by Ed Tobias Using the Floodlight App to Track My MS Over the past several weeks, I’ve been using an app called Floodlight to track my ability to live with my multiple sclerosis (MS). It measures things such as my balance, finger dexterity, walking speed, and cognitive ability. It even knows if I’m keeping myself shuttered in my apartment or…
June 27, 2019 Columns by Laura Kolaczkowski Could Shortened Infusion Times for Ocrevus Become a Reality? Users of the disease-modifying therapy Ocrevus (ocrelizumab) share a common complaint: the length of time the infusions take. It may seem petty, but an Ocrevus infusion consumes nearly an entire day. My typical infusion involves checking into the clinic, being screened by the infusion nurse for any changes, taking…
June 7, 2019 Columns by Ed Tobias My MS Has Been No Sweat. Has Yours, Too? I worked up a little sweat when I was exercising the other day. It was just a tiny bit on my forehead, but it was something I hadn’t felt in many years. I’ve lived with MS since 1980, and before now, I can’t remember the last time I felt sweaty.
June 6, 2019 News by Marisa Wexler, MS Roche, Sutter Health Testing Floodlight Mobile App That Monitors Patients’ MS Sutter Health, a California-based healthcare group, has partnered with the biotechnology company Roche to test a new mobile app that aims to improve monitoring of symptoms in people who have multiple sclerosis (MS). The app, called Floodlight, “may give neurologists access to meaningful, actionable patient data to…
May 29, 2019 News by Mary Chapman Corrona Expands MS Patient Registry to Include Genentech CorronaĀ has expanded its collaborative multiple sclerosis (MS) U.S. patient registry to include Genentech, the first pharmaceutical company to participate. Established in 2017, the CorronaĀ MS Registry is a real-world U.S.-based registry, developed in collaboration with theĀ National MS Society.Ā Its goal is to help guide treatment decisions based on…
May 14, 2019 News by Jose Marques Lopes, PhD #AANAM ā Ocrevus Lowers Markers of Inflammation, Damage in Relapsing MS Patients, Phase 3 Trial Shows Treatment with Ocrevus (ocrelizumab) decreases the levels of neurofilament light chain (NfL) and immune B-cells in the serum and central nervous system of patients with relapsing multiple sclerosis (MS), according to results from a Phase 3 trial. The research, āOcrelizumab treatment reduced levels of neurofilament light chain and…
May 13, 2019 News by Joana Carvalho, PhD Ocrevus Approved in UK as First NHS Treatment for PPMS After firstĀ rejecting it due to cost-effectiveness concerns, the National Institute for Health and Care Excellence (NICE) has now approved the use of Ocrevus (ocrelizumab) for people in the U.K. with early, inflammatory primary progressive multiple sclerosis (PPMS). This means that PPMS patients living in the…
May 13, 2019 News by Marisa Wexler, MS #AANAM – Ocrevus Effective in RRMS Patients with Poor Responses to Other DMTs, Early Trial Data Suggest Early, one-year data from theĀ Phase 3 CHORDS study show that OcrevusĀ effectively prevents relapses and disease progression inĀ relapsing-remitting multiple sclerosis (RRMS) patients who have had poor responses to other disease-modifying therapies. These interim results were presented at the 2019 annual meeting of the American Academy of NeurologyĀ (AAN) in…
May 9, 2019 News by Jose Marques Lopes, PhD #AANAM – Greater Exposure to Ocrevus Means Less Risk of Disability Progression in MS Patients, Study Contends Higher exposure to Ocrevus (ocrelizumab) is associated with greater immune B-cell depletion in the blood, and lessened risk of disability progression in patients with relapsing multiple sclerosis (MS) and primary progressive disease (PPMS), according to new research. The study supporting that finding, āPharmacokinetics, Pharmacodynamics and…
April 18, 2019 Columns by Jennifer (Jenn) Powell The DMT Decision: Tried and True or Shiny and New? I spend a great deal of time in my head. I think. A lot. Perhaps I do so more than I should, but then again, it is a haven at times. My thoughts run the gamut from the serious to the inane. Today my thoughts…
April 15, 2019 News by Jose Marques Lopes, PhD Anne Cross, Neurologist with Pioneering Work into B-cells and MS, Awarded John Dystel Prize This year’sĀ John Dystel Prize for Multiple Sclerosis ResearchĀ is being awarded toĀ Anne H. Cross, a neurologist and MS chair in the department of neuroimmunology atĀ Washington University School of Medicine in St. Louis, for herĀ research into the role of immune B-cells in multiple sclerosisĀ attacks and new imaging…
March 1, 2019 News by Jonathan Grinstein #ACTRIMS2019 ā Use of Ocrevus at Cleveland Clinic Backs Phase 3 Trial Data Ocrevus (ocrelizumab) was shown to be aĀ highly effective therapy for people with multiple sclerosis (MS) in real-world clinical practice, according to Brandon Moss, MD, from theĀ Cleveland Clinic. The data was presented in a poster session Feb. 28, atĀ the Americas Committee…
February 8, 2019 Columns by Ed Tobias DMT Approvals for Medicare Users Decline While Costs Rise, Study Shows This probably won’t come as a surprise to you if you’re on Medicare: It’s getting harder to obtain approval for many of the disease-modifying therapies (DMTs) prescribed for people with multiple sclerosis (MS). I see complaints about this all the time on social media. Now, research reported in…
January 23, 2019 News by Jose Marques Lopes, PhD Favorable Efficacy and Similar Safety with Ocrevus in Relapsing MS, Study Finds Treatment with Ocrevus (ocrelizumab) has superior or comparable effectiveness and a similar safety profile to other available disease-modifying treatments (DMTs) for treating relapsing multiple sclerosis (MS), according to a new review study. The research, āSystematic review and network meta-analysis comparing ocrelizumab with other treatments for…